GlassScriptPhysician profile
Qutubuddin K Dar
NPI 1427083435
$15,251.42
in general payments reported to CMS, 2019-2025
38 companies · $1,747 in 2025
The $1,747 reported for 2025 was more than what 92% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,463 · 2020: $1,826 · 2021: $2,509 · 2022: $2,872 · 2023: $3,011 · 2024: $1,823 · 2025: $1,747.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,572 · Education: $9.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,572.13 |
| Education | $9.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,370.56 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $2,540.08 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Lilly USA, LLC | $1,098.14 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $1,076.89 | 2019-2025 | Repatha, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $925.84 | 2019-2025 | Ofev, Jardiance, Tradjenta |
| Novo Nordisk INC | $850.32 | 2019-2025 | Rybelsus, Ozempic |
| Electromed, INC. | $660.41 | 2019-2025 | Smartvest |
| Bayer Healthcare Pharmaceuticals INC. | $609.82 | 2021-2024 | |
| Amarin Pharma, INC. | $532.77 | 2019-2021 | |
| Pfizer INC. | $529.84 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $457.57 | 2019-2023 | Belsomra |
| Grifols USA, LLC | $450.22 | 2019-2025 | Prolastin-C Liquid |
| Genzyme Corporation | $294.44 | 2022-2025 | |
| Exact Sciences Corporation | $242.32 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Regeneron Healthcare Solutions, INC. | $214.44 | 2021-2025 | Dupixent |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Qutubuddin Dar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.